科研之友
微信
新浪微博
Facebook
分享链接
摘要
Metastatic renal cell carcinoma (mRCC) is a disease historically resistant to systemic cancer therapies. For several decades, the biological agents interferon and interleukin were the only available options, but they were fairly toxic and had low efficacy. However, the past several years have witnessed the introduction of novel effective therapies that have radically changed the treatment of metastastic and recurrent RCC. We review the already approved novel agents and discuss therapies in late-stage clinical trials.
- 出版日期2007-6
